Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
Key facts
- Who runs it
- Kaiser Permanente
- Where
- Oakland, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 1,500,000 people, planned
- Started
- 17 Aug 2023
- Expected to end
- May 2028
- Type of study
- Observational, 2 groups
- Treatments tested
- Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
- High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
- Record updated
- 5 August 2026
Who can take part
- Age
- 65 years and older
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Age ≥65 years at the time of influenza vaccination
- KPNC member at the time of vaccination
- Receive either aIIV4 or HD-IIV4 at a KPNC facility during the 2023/24 and/or 2024/25 influenza seasons
Who cannot take part
- Received either aIIV4 or HD-IIV4 in the inpatient setting
- Age <65 years at the time of influenza vaccination
- Receive more than one influenza vaccination during a single season period (i.e., 2023/24 or 2024/25 influenza seasons)
- Receive an influenza vaccination outside of KPNC
This trial is currently available in United States.
- Kaiser Permanente Northern California (entire region)Oakland, United StatesContact: Amber H. Hyman, PhD, MPHTaking people
About the trial
What the trial wants to find out
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24, 2024/25, and 2026/27 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.
The 2 groups in the trial
- Fluad Recipients
Kaiser Permanente Northern California members aged ≥65 years who receive Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
Treatment: Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4)
- Fluzone High-Dose Recipients
Kaiser Permanente Northern California members aged ≥65 years who receive High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Treatment: High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Relative Vaccine Effectiveness of Adjuvanted Inactivated Influenza Vaccine (aIIV) vs High-Dose Inactivated Influenza Vaccine (HD-IIV) for Prevention of Lab-Confirmed Influenza Among Adults ≥65 Years of Age in the United States
- Publications
- Record updated
- 5 August 2026